<DOC>
	<DOCNO>NCT01424514</DOCNO>
	<brief_summary>The purpose study assess pharmacodynamic ( PD ) effect ( Total Symptom Score ( TSS ) individual component : rhinorrhoea , nasal congestion , post-nasal drip ) intranasal , repeat dose SB-705498 non-allergic rhinitis ( NAR ) patient elicit cold dry air challenge environmental exposure chamber ( EEC ) . SB-705498 selective antagonist transient receptor potential vanilloid-1 ( TRPV1 ) ligand gate ion channel . TRPV1 cation permeable ion channel activate several physiological factor , heat , proton ( pH ) , osmotic stress , eicosanoid derivative , anandamide , product inflammation , histamine , prostaglandins bradykinin . In nose , local TRPV1 express sensory C-fibres think play key role development nasal hyper-responsiveness environmental provocateur . It propose block nasal sensory nerve stimulation may control nasal hyper-responsiveness therefore prevent induction rhinitis symptom . In context , preclinical evidence support target TRPV1 SB-705498 may attractive option . In study NAR patient randomise , double blind , placebo control cross design receive 14 day repeat dose 12mg intra-nasal SB-705498 daily . Whilst dose home , subject record symptom score document symptom . In addition , visit clinical unit , acoustic rhinometry , quality life questionnaire safety assessment monitor .</brief_summary>
	<brief_title>SB705498 Proof Concept Chamber Challenge Subjects With Non Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Deviations inclusion criterion allow potentially jeopardize scientific integrity study , regulatory acceptability subject safety . Therefore , adherence criterion specify protocol essential . A subject eligible inclusion study follow criterion apply : 1 . Diagnosis NAR , determine presence perennial rhinitis symptom last several month per year , 1 year attribute allergy , infection nasal abnormality . Positive history rhinitis symptom trigger environmental provocateur ( e.g . weather change , irritant , air pollution etc ) , allergens . 2 . Normal level total plasma IgE negative allergy skin Rast test common aeroallergens . 3 . Male female 18 65 year age inclusive . 4 . A female subject eligible participate : Nonchildbearing potential define premenopausal female \documented tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 84 day postlast treatment administration . 5 . Male subject female partner childbearing potential must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 84 day postlast treatment administration . 6 . Body weight ≥ 50 kg ( male ) ≥45kg ( female ) BMI within range 19 29.9 kg/m2 ( inclusive ) . 7 . Capable give write informed consent , include compliance requirement restriction list consent form . 8 . Available complete require study measurement . 9 . Single QTc , &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . 10 . The subject must demonstrate screen TSS ≥ 4 ( 9 point scale ) screen visit 1 2 . 11 . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Deviations exclusion criterion allow potentially jeopardise scientific integrity study , regulatory acceptability subject safety . Therefore , adherence criterion specify protocol essential . A subject eligible inclusion study follow criterion apply : 1 . Nasal abnormality likely affect outcome study , i.e . nasal septal perforation , nasal polyp , nasal malformation . 2 . History frequent nosebleed . 3 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen 4 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 5 . Positive prestudy drug/alcohol/smoking screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids , benzodiazepine methadone 6 . A positive test HIV antibody . 7 . History regular alcohol consumption within 6 month study define : • An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . 8 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 9 . Exposure four new chemical entity within 12 month prior first dose day . 10 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Subjects use medication need basis , may participate study remain free medication follow period time prior visit : Nasal antihistamine : 48 hour Oral antihistamines A ( cetirizine , fexofenadine , loratadine , desloratadine ) : 7 day Oral antihistamine B ( others ) : 7 day Nasal decongestant : 24 hour Oral decongestant : 24 hour Nasal glucocorticosteroids : 4 week Inhaled glucocorticoid : 4 week Oral glucocorticosteroids : 12 week Oral leukotriene receptor antagonist : 7 day Oral 5lipoxygenase inhibitor : 7 day Oral methylxanthines : 7 day Subjects recent upper respiratory tract infection ( URTIs ) allow study nasal symptom completely resolve 3 week prior screen . 11 . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 12 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 13 . Pregnant female determine positive serum urine hCG test screen prior dosing . 14 . Lactating female . 15 . Unwillingness inability follow procedure outline protocol . 16 . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>